Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 9/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926904 | 0.92 | CTSA (0.50) | CTSACYP26A1KMT2AMAPTXBP1 | |
| SCHEMBL6101137 | 0.88 | CYP26A1 (0.47) | CTSACYP26A1KMT2AMEN1 | |
| SCHEMBL3978076 | 0.87 | EGLN2 (0.47) | CTSACYP26A1KMT2AMAPTXBP1 | |
| SCHEMBL5926694 | 0.86 | ITGB1 (0.47) | ITGB1ITGA4 | |
| SCHEMBL5926915 | 0.85 | TACR3 (0.41) | CTSACYP26A1KMT2AMAPTXBP1 | |
| SCHEMBL5926316 | 0.84 | CNR1 (0.42) | CTSACYP26A1KMT2AMAPTXBP1 | |
| SCHEMBL3992039 | 0.83 | CTSA (0.44) | CTSACYP26A1ITGB1 | |
| SCHEMBL5926299 | 0.83 | CTSA (0.43) | CTSACYP26A1KMT2AMAPTXBP1 | |
| SCHEMBL5926161 | 0.82 | CASP3 (0.42) | CTSAKMT2AMAPTXBP1 | |
| SCHEMBL5926269 | 0.82 | CTSA (0.41) | CTSAKMT2AMAPTXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CTSA 426/4885KCNA5 1021/4885CYP26A1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.